Nuclear medicine technology for diagnosisof neuroendocrine tumors
Abstract
This article is the review of issues of the literature for the past 10 years and is dedicated to the analysis of the radiopharmaceuticals and efficacy of the novel nuclear medicine technologies for the diagnosis, staging and prognosis of neuroendocrine tumors. Diagnostic efficacy of a scintigraphy and a positron emission tomography for detection of gastroenteropancreatic and lung carcinoid, medullary thyroid cancer, pheochromocytoma and haraganglioma and choice of radiopharmaceuticals were demonstrated by the results of the clinical studies. The causes of false positive and falce negative results were specified.
About the Authors
D. V. Ryzhkova
V.A. Almazov Federal Heart, Blood and Endocrinology Centre, St-Petersburg
Russian Federation
Russian Federation
D. N. Тikhonova
V.A. Almazov Federal Heart, Blood and Endocrinology Centre, St-Petersburg
Russian Federation
Russian Federation
E. N. Grineva
V.A. Almazov Federal Heart, Blood and Endocrinology Centre, St-Petersburg
Russian Federation
Russian Federation
References
1. Афанасьев С.Г., Авдеев С.В., Пак А.В. и др. Опыт лечения АКТГ-эктопированной опухоли легкого//Сибирский онкологический журнал. 2009. № 6 (36). С. 83-86
2. Егоров А.В., Кузин Н.М. Вопросы диагностики нейроэндокринных опухолей поджелудочной железы//Практическая онкология. 2005. Т. 6, № 4. С. 206-212
3. Имянитов Е.Н. Эпидемиология и биология нейроэндокринных опухолей//Практическая онкология. 2005. Т. 6, № 4. С. 202-205
4. Ларенков А.А., Кодина Г.Е., Брускин А.Б. Радионуклиды галлия в ядерной медицине: радиофармацевтические препараты на основе изотопа 68Ga//Медицинская радиология и радиационная безопасность. 2011. Т. 56, № 5. С. 56-73
5. Латыпов В.Р., Попов О.С., Вусик А.Н., Латыпова В.Н., Гейдаров Р.Я. Особенности и результаты хирургического лечения пациентов с опухолями надпочечников//Сибирский онкологический журнал. 2010. № 1 (37). С. 56-60
6. Ширяев С.В. Эмиссионная томография в комплексной диагностике опухолевых поражений печени: Автореф. дис. … д-ра мед. наук. М., 2009. 23 с
7. Ahlstroem H., Eriksson B., Bergstroem M. et al. Pancreatic neuroendocrine tumours: Diagnosis with PET//Radiology. 1995. Vol. 195. P. 333-337
8. Alexander K., Putzer D., Uprimny C. et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine//Eur. J. Nucl. Med. Mol. Imaging. 2011. Vol. 38. P. 865-887
9. Ambrosini V., Tomassetti P., Castellucci P. et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-enteropancreatic and lung neuro-endocrine tumours//Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. P. 1431-1438
10. Antunes P., Ginj M., Zhang H. et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals//Eur. J. Nucl. Med. Mol. Imaging. 2007. Vol. 34. P. 982-993
11. Bansal R., Tierney W., Carpenter S. et al. Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors//Gastrointest. Endoscop. 1999. Vol. 49 (1). P. 19-25
12. Beheshti M., Pеocher S., Vali R. et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT//Eur. Radiol. 2009. Vol. 19. P. 1425-1434
13. Binderup T., Knigge U., Loft A., Federspiel B. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors//Clin. Cancer Res. 2010. Vol. 16 (3). P. 978-985
14. Esser J.P., Krenning E.P., Teunissen J.J. et al. Comparison of [(177) Lu-DOTA(0),Tyr (3)]octreotate and [(177)Lu-DOTA(0),Tyr (3)]octreotide: which peptide is preferable for PRRT?//Eur. J. Nucl. Med. Mol. Imaging. 2006. Vol. 33. P. 1346-1351
15. Ezziddin S., Logvinski T., Yong-Hing C. et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors//J. Nucl. Med. 2006. Vol. 47. P. 223-233
16. Fanti S., Ambrosini V., Tomassetti P. et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET//Biomed. Pharmacother. 2008. Vol. 62. P. 667-671
17. Frilling A., Sotiropoulos G.C., Radtke A. et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors//Ann. Surg. 2010. Vol. 252. P. 850-856
18. Gabriel M., Decristoforo C., Kendler D. et al. 68Ga-DOTA-Tyr3octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT//J. Nucl. Med. 2007. Vol. 48. P. 508-518
19. Gibril F., Curtis L.T., Termanini B. et al. Primary cardiac gastrinoma causing Zollinger-Ellison syndrome//Gastroenterology. 1997. Vol. 112 (2). P. 567-574
20. Gibril F., Reynolds J.C., Doppman J.L. et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastaticgastrinomas//Ann. Intern. Med. 1996. Vol. 125. P. 26-34
21. Haug A., Auernhammer C.J., Wängler B. et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours//Eur. J. Nucl. Med. Mol. Imaging. 2009. Vol. 36. P. 765-770
22. Hofmann M., Maecke H., Borner R. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data//Eur. J. Nucl. Med. 2001. Vol. 28. P. 1751-1757
23. Imani F., Agopian V.G., Auerbach M.S. et al. 18F-FDOPAPET and PET/CT accurately localize pheochromocytomas//J. Nucl. Med. 2009. Vol. 50. P. 513-519
24. Jacobson A.F., Deng H., Lombard J. et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis//J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 2596-2606
25. Jager P., Chirakal R., Marriott C.J. et al. 6-L-18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications//J. Nucl. Med. 2008. Vol. 49. P. 573-586
26. Jindal T., Kumar A., Venkitaraman B. et al. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids//Korean J. Intern. Med. 2010. Vol. 25. P. 386-391
27. Kaltsas G., Korbonits M., Heintz E. et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors//J. Clin. Endocrinol. Metab. 2001. Vol. 86. P. 895-902
28. Katlas G.A., Mukherjee J.J., Grossman A.B. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours//Ann. Oncol. 2001. Vol. 12. Suppl. 2. S. 47-50
29. Kauhanen S., Seppanen M., Minn H. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or b-cell hyperplasia in adult patients//J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 1237-1244
30. Kauhanen S., Seppaеnen M., Ovaska J. et al. The clinical value of [18F] fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors//Endocr. Relat. Cancer. 2009. Vol. 16. P. 255-265
31. Koopmans K.P., de Groot J.W., Plukker J.T. et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation//J. Nucl. Med. 2008. Vol. 49. P. 524-531
32. Koopmans K.P., Neels O.C., Kema I.P. et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenylalanine and 11C-5-hydroxy-tryptophan positron emission tomography//J. Clin. Oncol. 2008. Vol. 26. P. 1489-1495
33. Koukouraki S., Strauss L.G., Georgoulias V. et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy//Eur. J. Nucl. Med. Mol. Imaging. 2006. Vol. 33. P. 460-466
34. Kowalski J., Henze M., Schuhmacher J. et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors//Mol. Imaging Biol. 2003. Vol. 5. P. 42-48
35. Kwekkeboom D., Krenning E.P., de Jong M. Peptide receptor imaging and therapy//J. Nucl. Med. 2000. Vol. 41. P. 1704-1713
36. Kwekkeboom D.J., Teunissen J.J., Bakker W.H. et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors//J. Clin. Oncol. 2005. Vol. 23. P. 2754-2762
37. Lebtahi R., Cadiot G., Sarda L. et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors//J. Nucl. Med. 1997. Vol. 6. P. 853-858
38. McEwan A.J., Shapiro B., Sisson J.C. et al. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors//Semin. Nucl. Med. 1985. Vol. 15. P. 132-153
39. Minn H., Kauhanen S., Seppaenen M. et al. 18F-FDOPA: A Multiple-Target Molecule//J. Nucl. Med. 2009. Vol. 50. P. 1915-1918
40. Mohnike K., Blankenstein O., Minn H. et al. [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism//Horm. Res. 2008. Vol. 70. P. 65-72
41. Nielsen J.T., Nielsen B.V., Rehling M. Location of adrenal medullary pheochromocytoma by I-123-metaiodobenzylguanidine SPECT//Clin. Nucl. Med. 1996. Vol. 21. P. 695-699
42. Orlefors H., Sundin A., Ahlstrоm H. et al. Positron Emission Tomography with 5-hydroxytryptophan in Neuroendocrine tumors//J. Clin. Oncol. 1998. Vol. 16. P. 2534-2542
43. Orlefors H., Sundin A., Garske U. et al. Whole-body (11)C-5hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin recep tor scintigraphy and computed tomography//J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 3392-3400
44. Prasad V., Ambrosini V., Hommann M. et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT//Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37. P. 67-77
45. Putzer D., Gabriel M., Henninger B. et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy//J. Nucl. Med. 2009. Vol. 50. P. 1214-1221
46. Raber M.N., Faintuch J., Abbruzzese J.L. et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastaticcarcinomaof unknownprimaryorigin//Ann.Oncol.1991. Vol. 2. P. 519-520
47. Srirajaskanthan R., Kayani I., Quigley A.M. The Role of 68GaDOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy//J. Nucl. Med. 2010. Vol. 51. P. 875-882
48. Sundin А. Nuclear imaging of neuroendocrine tumours//Best Pract. Res. Clin. Endocrinol. Metab. 2007. Vol. 21 (1). P. 69-85
49. Taieb D., Tessonnier L., Sebag F. et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas//Clin. Endocrin. (Oxf). 2008. Vol. 69. P. 580-586
50. Termanini B., Gibil F., Reynolds J.C. et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management//Gastroenterology. 1997. Vol. 112. P. 335-347
51. Treglia G., Castaldi P., Rindi G. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis//Endocrine. 2012. Vol. 42. P. 80-87
52. Wiseman G.A., Pacak K., O’Dorisio M.S. et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial//J. Nucl. Med. 2009. Vol. 50. P. 1448-1454
Review
For citations:
Ryzhkova D.V., Тikhonova D.N., Grineva E.N. Nuclear medicine technology for diagnosisof neuroendocrine tumors. Siberian journal of oncology. 2013;1(6):56-63. (In Russ.)
Views:
683
Email this article 
